BioTech 365

MARCH 1, 2021

ERS Genomics Expands Team With Appointment of Jon Kratochvil as VP Business Development ERS Genomics Expands Team With Appointment of Jon Kratochvil as VP Business Development Jon Kratochvil joins as Vice President for Business Development & Licensing for North America … Continue reading →

Business Development 40

Business Development Genome Genomics Development 40

pharmaphorum

SEPTEMBER 28, 2022

” ArsenalBio’s platform makes use of automation, large-scale genome engineering, using technologies like CRISPR-based gene-editing, and machine learning and artificial intelligence algorithms to design, build, and test cell therapies.

Gene Editing 59

Gene Editing Genome Genomics Engineer 59

The Pharma Data

NOVEMBER 3, 2020

It may also allow for priority or rolling review of a company’s Biologics License Application (BLA). LogicBio’s proprietary genome editing technology platform, GeneRide, enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination.

Clinical Trials 40

Clinical Trials Clinical Trials Gene Editing Genome 40

The Pharma Data

NOVEMBER 5, 2020

VectivBio AG – Based in Switzerland, VectivBio named Sarah Holland as chief business officer and Aditya Venugopal as head of business development. Most recently, Holland served as Global Head of licensing at Lonza AG. Prior to Lonza, she led External Science and Partnering across the globe for Sanofi R&D.

Genome 40

Genome Genomics Medicine Life Science 40

The Pharma Data

JANUARY 4, 2021

. Kiromic’s deep understanding of the tumor micro environment (TME) and the tumors’ escape and masking mechanisms led to development of a promising platform for chimeric antigen receptor therapy (CAR-T). We believe our allogenic CAR-T platform is significantly stronger with chPD1 target licensed from Longwood University.

In-Vivo 40

In-Vivo Development Immune Response Big Data 40

The Pharma Data

NOVEMBER 15, 2020

Prior to Celgene, she held leadership roles in marketing, sales and new business development from 2002 to 2011 at Johnson & Johnson. Most recently, she was a senior executive at Celgene Corporation, where she led corporate strategy from 2012 to 2017. Before that, Ms.

Clinical Trials 40

Clinical Trials Clinical Trials Production Trials 40

pharmaphorum

OCTOBER 1, 2021

It has made Oxford Nanopore’s chief executive and cofounder Gordon Sanghera an on-paper fortune of £63 million, while another cofounder – chief business development officer Spike Willcocks – is now worth £30 million. Chief technology officer Clive Brown is also sitting on a £10 million stake.

Marketing 52

Marketing Genome Genomics Business Development 52